Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326310 · ClinicalTrials.gov registry record · Phase 1
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
A Phase 1 study of Chronic Myeloid Leukemia and Myelofibroses, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03326310 is a Phase 1 study of Chronic Myeloid Leukemia and Myelofibroses that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 18 participants, below the 209-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03326310, a Phase 1 study of Chronic Myeloid Leukemia and Myelofibroses, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A patient will be taken off study for reasons described in detail in section 3.12 including disease progression, unacceptable toxicity, inter-current illness, withdrawal of consent, or at the discretion of the investigator. Patients will be followed for 12 weeks after the last dose of study drug, until any study treatment related toxicities have stabilized, or until death. The total duration of the study is expected to be approximately 24 months.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Selumetinib
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2027-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03326310
The ClinicalTrials.gov registry entry for NCT03326310 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (91% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT03326310 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03326310 about?
NCT03326310 is a clinical study titled "Selumetinib and Azacitidine in High Risk Chronic Blood Cancers". This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A pa...
What is the current status of trial NCT03326310?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-09-04. Estimated completion is 2027-09-04.
What conditions does trial NCT03326310 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, Myelofibroses.
What interventions are being tested in trial NCT03326310?
The interventions under investigation include: Azacitidine (DRUG), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT03326310?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03326310 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
RECRUITING · Phase 1
-
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.